Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 656

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 656
---
 |     | For the six-month period ended 
                   December 31, 
                           2024 |     |    2023 |
|:--------------------|:----|-------------------------------:|:----|--------:|
| Heritas Diagnostics |     |                        696,606 |     | 672,336 |
| Rewell              |     |                        138,176 |     |  31,056 |
| Total revenues      |     |                        834,782 |     | 703,392 |

Contract liability As of December 31, 2024 and June 30, 2024, contract liabilities consisted of the following.

|                          |     |        As of 
 December 31, 
         2024 |     |    As of 
 June 30, 
     2024 |
|:-------------------------|:----|-------------:|:----|---------:|
| Heritas Diagnostics      |     |      112,672 |     |   87,170 |
| Rewell                   |     |        5,366 |     |    7,812 |
| Total contract liability |     |      118,038 |     |   94,982 |

The Group recognizes as contract liabilities the amount of advance payments and billings that exceed recognized revenue. In the case of the Rewell test services, customer revenue is generally billed upon collection and recognized at the time when the corresponding service is provided to the customers (this is, when control of the deliverable is transferred). To the extent that the service is not provided by the reporting date, the amount is recognized as a contract liability. 17.Expenses by nature Expenses are classified by their function in the statement of operations, The following tables provide additional disclosure regarding their nature and their relationship to the function for the six -monthended December 31, 2024, and 2023:

|                                                              |     |   Cost of 
     sales |     | Research and 
  development 
     expenses |     |    General and 
 administrative 
       expenses |     |  Selling 
 expenses |     |      For the 
    six-month 
        ended 
 December 31, 
         2024 |
|:-------------------------------------------------------------|:----|----------:|:----|-------------:|:----|---------------:|:----|---------:|:----|-------------:|
| Laboratory supplies                                          |     |   488,847 |     |        5,192 |     |